<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sinclair, Heather Q.</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Stone, Gregg</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Selected Updates on Cardiometabolic Risk</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2009</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2009-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">29-30</style></pages><abstract><style  face="normal" font="default" size="100%">The metabolic syndrome (MetS) refers to a cluster of metabolic abnormalities that are caused by insulin resistance, which is often associated with intra-abdominal (visceral) obesity, a high-risk form of being overweight/obesity. Cardiometabolic risk encompasses overall cardiovascular disease (CVD) risk that results from traditional risk factors (age, sex, smoking, hypertension, LDL cholesterol, HDL cholesterol, diabetes) and from the additional risks of intra-abdominal obesity and related features of the MetS. Questions remain about the clinical implications of MetS and whether MetS contributes to global CVD risk. These issues were the focus of a special symposium that was organized by the International Chair on Cardiometabolic Risk at the 15th International Symposium on Atherosclerosis 2009 in Boston, Massachusetts, USA.</style></abstract><number><style face="normal" font="default" size="100%">4</style></number><volume><style face="normal" font="default" size="100%">9</style></volume></record></records></xml>